TITLE

SECTION 7 METABOLIC DISORDERS

PUB. DATE
September 2014
SOURCE
MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p131
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on several drugs for the treatment of obesity. The Belviq weight-loss medication from pharmaceutical firm Eisai Co. Ltd. should be used together with a reduced-calorie diet and weight maintenance to treat obesity. Obese patients are advised to take the Qsymia weight loss pill once a day in the morning and its adverse reactions include paraesthesia. The contraindications of the Xenical lipase inhibitor include chronic malabsorption syndrome and pregnancy.
ACCESSION #
98790981

 

Related Articles

  • Topiramate withdrawal.  // Reactions Weekly;6/2/2007, Issue 1154, p22 

    The article presents a case report of an obese man who experienced rebound weight gain following topiramate withdrawal. The man had a body mass index of 32 and a history of multiple dietary treatments followed by weight gain and an unsuccessful orlistat treatment. The man stopped further...

  • ORLISTAT.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p622 

    The article presents information on orlistat, an antiobesity drug and lipase inhibitor, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • orlistat. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p569 

    An encyclopedia entry for "orlistat" is presented. It refers to an anti-obesity drug used with a slimming diet for the treatment of severe obesity. It is different from appetite suppressants in that orlistat acts on the gastrointestinal tract, preventing the digestion of fats by lipases. The...

  • The uphill battle facing antiobesity drugs. Daubresse, M; Alexander, G C // International Journal of Obesity;Mar2015, Vol. 39 Issue 3, p377 

    The authors reflect on the limited adoption of antibobesity drugs in clinical practice in the U.S. despite their association with short-term weight loss. They cite several antiobesity drugs that were withdrawn from the market due to the occurrence of adverse effects including sibutramine and...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • Efficacy and Tolerability of the Association of Sibutramine and Orlistat for Six Months in Overweight and Obese Patients. Halpern, Alfredo; Pepe, Renata B.; Monegaglia, Ana Paola; Beyruti, Mônica; de Melo, Maria Edna; Mancini, Marcio C. // Journal of Obesity;2010, Vol. 2010, p1 

    Objective. To assess the efficacy and tolerability of the association sibutramine (10-20 mg/day) and orlistat (120 mg 2-3 times a day) in the treatment of obesity in a six-month open trial. Methods. 446 overweight and obese patients who sought treatment for obesity in a private clinic were...

  • Managing obesity in adults in primary care. Plourde, Gilles; Prud'homme, Denis // CMAJ: Canadian Medical Association Journal;6/12/2012, Vol. 184 Issue 9, p1039 

    In this article, the author presents his views on the prevention and treatment of obesity and also believes that weight loss counseling must be a part of primary care for adults. He mentions that the two most common methods of assessing obesity and overweight are body mass index (BMI) and waist...

  • Obesity: Health costs estimated at $75 billion.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p50 

    The article provides an overview of the anti-obesity drug market in the United States. Data showed that 32 percent of American adults are obese, which represents more than 60 percent increase in the prevalence of obesity since 1993. Overweight and obesity are associated with an increased risk of...

  • A pharmacologic approach to obesity. Lucas, Charles P.; Segal, Karen R.; Hauptman, Jonathan // Contemporary OB/GYN;Jun2000, Vol. 45 Issue 6, p18 

    Evaluates the effectiveness of orlistat for the treatment of obesity. Gender-specific effects of obesity; Effect of orlistat on weight loss; Side effects of orlistat. INSET: Fighting obesity.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics